论文部分内容阅读
目的探讨耐药蛋白DNA拓扑异构酶Ⅱ(TopoⅡ)和谷胱甘肽-S-转移酶-π(GST-π)与乳腺浸润性导管癌的临床病理特征及分子分型的关系。方法原发性乳腺浸润性导管癌患者125例,应用免疫组化SP法检测TopoⅡ和GST-π的表达。结果 TopoⅡ和GST-π阳性表达率分别为75.2%和44.8%。TopoⅡ的阳性表达在Luminal-B型和人表皮生长因子受体2(Her-2)过表达型的阳性率高于Luminal-A型(90.9%和87.5%vs.60.7%)(P<0.05);TopoⅡ表达率随着肿瘤组织学分级的增加而升高(P<0.05)。GST-π的表达在年龄、肿瘤大小、淋巴结转移、组织学分级、分子分型以及临床分期中均无明显差异。结论在浸润性导管癌中,TopoⅡ与肿瘤的恶性程度及Her-2基因的过表达有关。
Objective To investigate the relationship between the expression of DNA topoisomerase II (Topo II) and glutathione-S-transferase-π (GST-π) and the clinicopathological features and molecular typing of breast invasive ductal carcinoma. Methods 125 patients with primary breast invasive ductal carcinoma were examined for the expression of TopoII and GST-π by immunohistochemical SP method. Results The positive rates of TopoII and GST-π were 75.2% and 44.8%, respectively. The positive expression rate of TopoII was higher in Luminal-B and human epidermal growth factor receptor 2 (Her-2) overexpression than in Luminal-A (90.9% and 87.5% vs. 60.7%) (P<0.05). The TopoII expression rate increased with the increase of tumor histological grade (P<0.05). GST-π expression was not significantly different in age, tumor size, lymph node metastasis, histological grade, molecular typing, and clinical stage. Conclusion In invasive ductal carcinoma, TopoII is associated with the degree of malignancy and overexpression of Her-2 gene.